Research Article

FOXM1 Promotes Drug Resistance in Cervical Cancer Cells by Regulating ABCC5 Gene Transcription

Figure 1

(a) Colony formation assay of Caski and Caski/Taxol cells cultured with 80 μM paclitaxel for 48 h. Magnification, 400x. (b) IC50 dose of paclitaxel for Caski cells was 50.55 μM (95% CI, 39.95-63.97) and 88.82 μM (95% CI, 79.92-98.70) for Caski/Taxol cells. The Caski/Taxol cells exhibited significantly increased viability when treated with paclitaxel compared with the Caski cells. (c) Cell cycle distribution analysis showed that 74.7% cells of Caski/Taxol cells were in the G0/G1 stage, compared with 49.81% of the Caski cells. Additionally, 15.94 and 9.36% of Caski/Taxol cells were in the S and G2/M stages, compared with 32.24 and 17.95% of Caski cells. Compared with Caski cells: . Caski/Taxol: paclitaxel-resistant Caski cells; CI: confidence interval.